未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Charge-Transport Divergence in Ultrastable Heterometal-Oxo Clusters Exerting Significant Effect on Photoreactivity在超稳定异金属-氧簇中的电荷传输分歧对光反应性产生显著影响
Shi, Jing-Wen; Li, Ning; Liang, Yan; Xu, Shan; Dong, Long-Zhang; Zhang, Dongdi; Niu, Jingyang; Li, Run-Han; Liu, Jiang; Li, Shun-Li; Lan, Ya-Qian
分享
收藏
分享
收藏B-cell-specific checkpoint molecules that regulate anti-tumour immunity (vol 619, pg 348, 2023)B细胞特异性检查点分子对肿瘤免疫的调控(vol 619, pg 348, 2023)
Bod, Lloyd; Kye, Yoon-Chul; Shi, Jingwen; Triglia, Elena Torlai; Schnell, Alexandra; Fessler, Johannes; Ostrowski, Stephen M.; Von-Franque, Max Y.; Kuchroo, Juhi R.; Barilla, Rocky M.; Zaghouani, Sarah; Christian, Elena; Delorey, Toni Marie; Mohib, Kanishka; Xiao, Sheng; Slingerland, Nadine; Giuliano, Christopher J.; Ashenberg, Orr; Li, Zhaorong; Rothstein, David M.; Fisher, David E.; Rozenblatt-Rosen, Orit; Sharpe, Arlene H.; Quintana, Francisco J.; Apetoh, Lionel; Regev, Aviv; Kuchroo, Vijay K.
分享
收藏First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析
Xu, Jianming; Kato, Ken; Hubner, Richard; Park, Sook Ryun; Kojima, Takashi; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Wu, Hongqian; Wang, Lei; Yan, Sebastian; Shi, Jingwen; Kadva, Alysha; Yoon, Harry H.
分享
收藏Characterization, sources, and risk assessment of atmospheric PM10-bound NPAHs and OPAHs in the core area of the Ili River Valley, China
Ji, Yaqin; Xiao, Yang; Wang, Miao; Wang, Bingbing; Yang, Xiawei; Shi, Jingwen; Xu, Wenju; Yang, Wen; Zhao, Xueyan
分享
收藏Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study替雷利珠单抗(TIS)联合化疗(Chemo)对比安慰剂(PBO)联合化疗作为晚期胃或胃食管结合部腺癌(GC/GEJC)的一线(1L)治疗方案:RATIONALE-305研究中亚洲亚组患者的报告结局(PRO)
Kato, K.; Xu, R-H.; Oh, D-Y.; Bai, Y.; Shi, J.; Lee, K-W.; Hirano, H.; Xu, H.; Sheng, T.; Barnes, G.
分享
收藏